June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Topical interferon treatment of conjunctival melanocytic lesions: a clinical and morphological study
Author Affiliations & Notes
  • Peter Lipscomb
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Travis Peck
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Filippo Crimí
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Zeynel Karcioglu
    Department of Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Footnotes
    Commercial Relationships   Peter Lipscomb, None; Travis Peck, None; Filippo Crimí, None; Zeynel Karcioglu, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4369. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Peter Lipscomb, Travis Peck, Filippo Crimí, Zeynel Karcioglu; Topical interferon treatment of conjunctival melanocytic lesions: a clinical and morphological study. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4369.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effect of topical interferon α-2b therapy on conjunctival melanoma (CM) and primary acquired melanosis (PAM) and study the morphologic changes after topical interferon α-2b treatment.

Methods : Eight patients with biopsy-proven CM and/or PAM were treated with topical Interferon α-2b following excision and cryotherapy. One drop of interferon α-2b (1 M units/ml/tid) was repeated in 3-month cycles. Light microscopic (LM) and electron microscopic (EM) examinations were done after 3 months of topical interferon treatment in one case.

Results : Four eyes showed significant pigmentation loss within one cycle of treatment. Two patients required a second cycle of treatment and two patients needed a second surgery/cryotherapy. LM and EM studies showed a decrease in the number of melanocytes and melanin production and clustering of pigment laden phagocytes around subconjunctival blood vessels.

Conclusions : Topical interferon α-2b is an effective and complication-free agent for the adjuvant treatment of melanocytic conjunctival lesions. The LM and EM studies were not useful towards the understanding of interferon α-2b's mechanism of action on proliferating melanocytes.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×